fashion -WSS

fashion

author：leisure time 2025-10-01 00:59:28 - browse：679

Sammy Kimball for STAT

Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Will the IRA bring competition to the biologics market?

explore

WSS

Readout LOUD podcast: mifepristone case, GLP

There's no autism epidemic. It's an autism diagnosis epidemic

A common UTI test for kids haunts adults as a traumatic 'nightmare'

IRA could hurt research into orphan drugs for rare diseases

Telehealth for opioid use disorder is lifesaving

Merck drug for rare lung condition set for approval in U.S.

knowledge

fashion

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Psychedelics group wrestles with new pharma identity

Regeneron agrees to White House price limits on anti

Peter Hotez and the public health issue of online harassment

Acelyrin, a rare IPO success, stumbles in its first big test

Drug repurposing or repositioning? The language matters

The Readout: Lenmeldy, GLP

In Memoriam: Notable people who died in 2023

How medical schools plan to diversify without affirmative action

hotspot

Will the IRA bring competition to the biologics market?

Abortion pill case raises question: who can sue the FDA?

Diverse clinical trials: Why aren’t we there yet?

Food makers to regulators: Ultra

How housing is health care on Long Island

Donor acceptance rates hint at racial, gender bias in heart transplants: study

explore

Wikipedia

explore

leisure time